Objectives: To establish prevalence, management and long-term outcomes of osteonecrosis (ON) in young people diagnosed with acute lymphoblastic leukaemia (ALL) between 2003 and 2011. Design, setting, participants: This study assessed ON in 3113 patients aged 1–24 years who participated in the UK national leukaemia study UKALL 2003. UKALL 2003 recruited patients in 40 UK hospitals between 2003 and 2011 and included patients between ages 1 and 25 diagnosed with ALL. Results: 170 patients were diagnosed with ON, giving a prevalence of 5.5%. The multivariable analysis showed that the risk of ON was highest for children aged between 10 and 20 years (ages 10–15 years, OR 23.7, 95% CI 14.8 to 38.0; ages 16–20 years, OR 22.5, 95% CI 12.7 to 39.8, c...
Abstract Treatment-related late effects have increasingly become important, since the majority of c...
Osteonecrosis and decline of bone density are serious side effects during and after treatment of chi...
Osteonecrosis is a dose-limiting toxicity in the treatment of pediatric acute lymphoblastic leukemia...
Osteonecrosis (ON) is a common disabling complication of treatment for patients with acute lymphobla...
Introduction: Osteonecrosis is a well-recognised treatment-related morbidity risk in patients diagno...
Osteonecrosis (ON) is a common disabling complication of treatment for patients with acute lymphobla...
PurposeWe studied cumulative incidence, risk factors, therapeutic strategies, and outcome of symptom...
Following a review of the literature describing the bone health of children, teenagers and young peo...
Osteonecrosis (ON) is a serious complication of acute lymphocytic leukaemia (ALL) or lymphoblastic l...
PURPOSE: We studied cumulative incidence, risk factors, therapeutic strategies, and outcome of sympt...
Purpose: To determine the prevalence of osteonecrosis (ON) in children following treatment of acute...
To access publisher's full text version of this article click on the hyperlink belowTreatment-relate...
Osteonecrosis (ON) is a known complication of acute leukemia (AL) management, affecting 1%–10% of yo...
BACKGROUND AND OBJECTIVES: Osteonecrosis (ON) is a potentially disabling complication of combinati...
Osteonecrosis is a significant adverse effect of treatment administered to children suffering from a...
Abstract Treatment-related late effects have increasingly become important, since the majority of c...
Osteonecrosis and decline of bone density are serious side effects during and after treatment of chi...
Osteonecrosis is a dose-limiting toxicity in the treatment of pediatric acute lymphoblastic leukemia...
Osteonecrosis (ON) is a common disabling complication of treatment for patients with acute lymphobla...
Introduction: Osteonecrosis is a well-recognised treatment-related morbidity risk in patients diagno...
Osteonecrosis (ON) is a common disabling complication of treatment for patients with acute lymphobla...
PurposeWe studied cumulative incidence, risk factors, therapeutic strategies, and outcome of symptom...
Following a review of the literature describing the bone health of children, teenagers and young peo...
Osteonecrosis (ON) is a serious complication of acute lymphocytic leukaemia (ALL) or lymphoblastic l...
PURPOSE: We studied cumulative incidence, risk factors, therapeutic strategies, and outcome of sympt...
Purpose: To determine the prevalence of osteonecrosis (ON) in children following treatment of acute...
To access publisher's full text version of this article click on the hyperlink belowTreatment-relate...
Osteonecrosis (ON) is a known complication of acute leukemia (AL) management, affecting 1%–10% of yo...
BACKGROUND AND OBJECTIVES: Osteonecrosis (ON) is a potentially disabling complication of combinati...
Osteonecrosis is a significant adverse effect of treatment administered to children suffering from a...
Abstract Treatment-related late effects have increasingly become important, since the majority of c...
Osteonecrosis and decline of bone density are serious side effects during and after treatment of chi...
Osteonecrosis is a dose-limiting toxicity in the treatment of pediatric acute lymphoblastic leukemia...